{"id":6304,"date":"2012-11-29T15:36:00","date_gmt":"2012-11-29T15:36:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/fdas-social-media-guidance-cliff-open\/"},"modified":"2019-02-21T01:18:24","modified_gmt":"2019-02-21T01:18:24","slug":"fdas-social-media-guidance-cliff-open","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/","title":{"rendered":"FDA’s “Social Media Guidance Cliff”: An Open Letter to Megan Clark Velez"},"content":{"rendered":"
\nFDA will communicate its progress towards accomplishing the requirements of the FDA Safety and Innovation Act (FDASIA) by updating an online chart\/database on a regular basis. This database\/website is called FDASIA-TRACK<\/a>.<\/div>\n

\nCurrently, the chart includes only those requirements with specific statutory dates set by Congress. “Additional deliverables will be added to the chart over time as FDA continues to advance its implementation planning efforts,” says the FDA.<\/p>\n

Of course, I am laser-focused on ONLY one “deliverable”: Draft guidance describing FDA policy regarding Internet promotion, including social media, of medical products regulated by FDA<\/b>. Congress has set 9-JULY-2014 as the deadline for this guidance.<\/p>\n

In order to be in step with current Congressional media jargon, I refer to this date as FDA’s “Social Media Guidance Cliff” although this “cliff” — and, IMHO, the “Fiscal Cliff” as well — is more like a slippery slope (see here<\/a>).<\/p>\n

\n<\/a><\/div>\n

\nIf you are a regular reader of Pharma Marketing Blog<\/i>, you know that I am not content to report the news. I also attempt to influence the people who make the news and goose things along by being a bit provocative.<\/p>\n

So, I have decided to send an email to the person listed as the contact for this deliverable — Megan Clark Velez, MPH, Office of the Commissioner — and ask her for a bit more transparency. I decided to make this an “open” email by publishing it below in the hopes that some of you may also contact Ms. Velez with your own questions. Her contact info:<\/p>\n

Megan Clark Velez, MPH
\nFood and Drug Administration
\n10903 New Hampshire Ave., WO1, Rm. 4316
\nSilver Spring, MD 20993
\nPhone 301-796-4830
\nEmail: megan.velez@fda.hhs.gov<\/a><\/p>\n

My email to Megan Clark Velez:<\/p>\n

\nDear Ms. Megan Clark Velez, <\/p>\n

\nYour email address was listed as the contact on the FDASIA-TRACK site for draft guidance regarding internet promotion, the deadline for which is 7\/9\/2014 (I call this the “Social Media Guidance Cliff”).<\/p>\n

The deadline seems far off, but FDA has supposedly been “serious” about issuing this guidance since the November, 2009, public hearing.<\/p>\n

Maybe you can answer a few questions:<\/p>\n

FDA has said that there may be several guidances in this category. “What had been envisioned as a massive, all-encompassing guidance on Internet promotion is being retooled as multiple guidances to address specific issues in the online realm,” Tom Abrams said (see http:\/\/bit.ly\/SgS21f<\/a>). Recent guidance for unsolicited requests for off-label info, for example, included some guidance for responding to such requests via social media. Will there be other guidance documents like this issued BEFORE the “Social Media Guidance Cliff”?<\/p>\n

If not “hidden” within other guidances, will there be any guidance SPECIFIC for social media prior to the deadline?<\/p>\n

If such “mini” guidances ARE issued prior to the “Social Media Guidance Cliff,” what question\/area posed at the November, 2009, hearing will the first such guidance document address?<\/p>\n

Whatever you can tell us — the general public and the pharma industry — about what the FDA is doing behind closed doors and progress being made to develop these guidances will be appreciated.<\/p>\n

Thank you for your attention to this matter and your much anticipated response!<\/p>\n

\nJohn Mack, Editor & Publisher
Pharma Marketing News\/Pharma Marketing Blog<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA will communicate its progress towards accomplishing the requirements of the FDA Safety and Innovation Act (FDASIA) by updating an online chart\/database on a regular basis. This database\/website is called FDASIA-TRACK. Currently, the chart includes only those requirements with specific statutory dates set by Congress. “Additional deliverables will be added to the chart over time […]<\/p>\n","protected":false},"author":2,"featured_media":10952,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[304,44,145,167],"topic":[],"acf":[],"yoast_head":"\nFDA's "Social Media Guidance Cliff": An Open Letter to Megan Clark Velez - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA's "Social Media Guidance Cliff": An Open Letter to Megan Clark Velez - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"FDA will communicate its progress towards accomplishing the requirements of the FDA Safety and Innovation Act (FDASIA) by updating an online chart\/database on a regular basis. This database\/website is called FDASIA-TRACK. Currently, the chart includes only those requirements with specific statutory dates set by Congress. “Additional deliverables will be added to the chart over time […]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2012-11-29T15:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-21T01:18:24+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2012\/11\/SM-Cliff.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"258\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/\",\"name\":\"FDA's \\\"Social Media Guidance Cliff\\\": An Open Letter to Megan Clark Velez - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2012-11-29T15:36:00+00:00\",\"dateModified\":\"2019-02-21T01:18:24+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA’s “Social Media Guidance Cliff”: An Open Letter to Megan Clark Velez\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA's \"Social Media Guidance Cliff\": An Open Letter to Megan Clark Velez - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/","og_locale":"en_US","og_type":"article","og_title":"FDA's \"Social Media Guidance Cliff\": An Open Letter to Megan Clark Velez - Pharma Marketing Network","og_description":"FDA will communicate its progress towards accomplishing the requirements of the FDA Safety and Innovation Act (FDASIA) by updating an online chart\/database on a regular basis. This database\/website is called FDASIA-TRACK. Currently, the chart includes only those requirements with specific statutory dates set by Congress. “Additional deliverables will be added to the chart over time […]","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/","og_site_name":"Pharma Marketing Network","article_published_time":"2012-11-29T15:36:00+00:00","article_modified_time":"2019-02-21T01:18:24+00:00","og_image":[{"width":400,"height":258,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2012\/11\/SM-Cliff.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/","name":"FDA's \"Social Media Guidance Cliff\": An Open Letter to Megan Clark Velez - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2012-11-29T15:36:00+00:00","dateModified":"2019-02-21T01:18:24+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/fdas-social-media-guidance-cliff-open\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"FDA’s “Social Media Guidance Cliff”: An Open Letter to Megan Clark Velez"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6304"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=6304"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6304\/revisions"}],"predecessor-version":[{"id":10953,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6304\/revisions\/10953"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/10952"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=6304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=6304"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=6304"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=6304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}